Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its first quarter 2018 financial results after the close of market on Tuesday, May 1, 2018 . Following the announcement, Veracyte will host a conference call and webcast
Toggle Summary Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma ® Xpression Atlas platform to


Date Event Details
Summary Toggle May 1, 2018 1:30 PM PDT
Veracyte First Quarter 2018 Financial Results Webcast
Summary Toggle Feb 27, 2018 1:30 PM PST
Veracyte Fourth Quarter and Full Year 2017 Financial Results Webcast


Title Documents

Veracyte Corporate Presentation, February 2018